Q-omics provides the consensus-scored MIDEAS profile across patient tissues and cancer cell-line models. MIDEAS expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MIDEAS is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, MIDEAS protein abundance shows 20,951 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, HNSC, and GBM as cancer lineages where MIDEAS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIDEAS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIDEAS survival associations across molecular data types. MIDEAS RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIDEAS RNA expression–survival associations across cancer types. High MIDEAS expression shows unfavorable associations in ACC, OV, UVM and LUSC, but favorable associations in BRCA and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for MIDEAS RNA expression.
This table summarizes MIDEAS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MIDEAS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIDEAS shows lower tumor expression in COAD, BLCA, LUAD, THCA and LUSC and higher tumor expression in HNSC. The HNSC box plot shows higher MIDEAS RNA expression in tumor versus normal tissue (log2 FC = +0.951, t-test p < 0.001).
This table shows molecular features associated with MIDEAS in patient tissues and cancer cell lines. In patient samples, MIDEAS shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MIDEAS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
